NCT01168895 - Study in COPD (Chronic Obstructive Pulmonary Disease) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions

InfectionPulmonary Disease, Chronic Obstructive

Interventions

DRUG

Cipro Inhale (Ciprofloxacin, BAYQ3939)

32.5 mg ciprofloxacin corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as single dose inhalation

DRUG

Cipro Inhale (Ciprofloxacin, BAYQ3939)

48.75 mg ciprofloxacin corresponding to 75 mg Ciprofloxacin Pulmosphere inhalation powder will be given as single dose inhalation

Trial Locations (1)

Großhansdorf